<DOC>
	<DOCNO>NCT02858362</DOCNO>
	<brief_summary>A Phase 2 Clinical Study Assess Activity Safety Utrophin Modulation SMT C1100 ( ezutromid ) Ambulatory Paediatric Male Subjects Duchenne Muscular Dystrophy ( DMD )</brief_summary>
	<brief_title>PoC Study Assess Activity Safety SMT C1100 ( Ezutromid ) Boys With DMD</brief_title>
	<detailed_description>This Phase 2 , open-label , study ass activity safety utrophin modulation SMT C1100 ( ezutromid ) 2500 mg administer orally bid ambulatory paediatric male subject DMD . Approximately 40 subject DMD enrol study . This study conduct multi-centre setting United Kingdom United States America comprise Screening Baseline Phase 28 day , 48-week open label Treatment Phase 30-day Safety Follow Phase .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Male Age â‰¥5 &lt; 10 year ( 5th birthday 10th birthday ) DMD diagnosis Willing able comply study procedure , include 2 muscle biopsy procedure Able undergo MRI Have use least 6 month stable dose systemic corticosteroid Ability walk 300 metre unassisted 80 % predict 6MWD Uncontrolled congestive heart failure ( CHF ) recent change CHF prophylaxis/treatment Use beta blocker , herbal supplement , BCRP substrates , SNRIs , SSRIs , tricyclic antidepressant , ADHD treatment methylphenidate PEA . Use counter , herbal prescription CYP2B6 , CYP1A1 CYP1A2 inhibitor , inducer substrate . Exposure investigational drug DMD interventional agent within 3 month ( except FORDMD Study participant permit ) Require daytime ventilator assistance Be dairy lactose intolerant Be smoker , use tobacco nicotine product expose daily passive smoking Use approve DMD medication anticipate use study ( steroid )</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DMD</keyword>
	<keyword>Muscular Dystrophy</keyword>
	<keyword>Utrophin</keyword>
	<keyword>Duchenne</keyword>
	<keyword>PhaseOut DMD</keyword>
</DOC>